155 related articles for article (PubMed ID: 27144829)
21. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
22. Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas.
Ramakrishnan V; Xu B; Akers J; Nguyen T; Ma J; Dhawan S; Ning J; Mao Y; Hua W; Kokkoli E; Furnari F; Carter BS; Chen CC
EBioMedicine; 2020 May; 55():102736. PubMed ID: 32361246
[TBL] [Abstract][Full Text] [Related]
23. BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53.
Nie E; Jin X; Wu W; Yu T; Zhou X; Zhi T; Shi Z; Zhang J; Liu N; You Y
Sci Rep; 2016 Dec; 6():39743. PubMed ID: 28000777
[TBL] [Abstract][Full Text] [Related]
24. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
Tso JL; Yang S; Menjivar JC; Yamada K; Zhang Y; Hong I; Bui Y; Stream A; McBride WH; Liau LM; Nelson SF; Cloughesy TF; Yong WH; Lai A; Tso CL
Mol Cancer; 2015 Nov; 14():189. PubMed ID: 26546412
[TBL] [Abstract][Full Text] [Related]
25. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
26. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
[TBL] [Abstract][Full Text] [Related]
27. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
28. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Schmid RS; Simon JM; Vitucci M; McNeill RS; Bash RE; Werneke AM; Huey L; White KK; Ewend MG; Wu J; Miller CR
Neuro Oncol; 2016 Jul; 18(7):962-73. PubMed ID: 26826202
[TBL] [Abstract][Full Text] [Related]
29. HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression.
Chen W; Xiao Z; Zhao Y; Huang L; Du G
Oncol Rep; 2013 Nov; 30(5):2495-501. PubMed ID: 23970362
[TBL] [Abstract][Full Text] [Related]
30. O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
Sasai K; Akagi T; Aoyanagi E; Tabu K; Kaneko S; Tanaka S
Mol Cancer; 2007 Jun; 6():36. PubMed ID: 17547775
[TBL] [Abstract][Full Text] [Related]
31. O6-Methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry.
Buccoliero AM; Castiglione F; Rossi Degl'Innocenti D; Paglierani M; Maio V; Gheri CF; Garbini F; Moncini D; Taddei A; Sardi I; Sanzo M; Giordano F; Mussa F; Genitori L; Taddei GL
J Chemother; 2008 Apr; 20(2):263-8. PubMed ID: 18467255
[TBL] [Abstract][Full Text] [Related]
32. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
[TBL] [Abstract][Full Text] [Related]
33. [Strategy for studying gene methylation: the example of MGMT].
Fina F; Nanni-Metellus I; Courdy C; Figarella-Branger D; Martin PM; Ouafik L
Ann Pathol; 2009 Nov; 29 Spec No 1():S37-9. PubMed ID: 19887248
[No Abstract] [Full Text] [Related]
34. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
35. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
[TBL] [Abstract][Full Text] [Related]
36. Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-Resistance.
Kwon SM; Kang SH; Park CK; Jung S; Park ES; Lee JS; Kim SH; Woo HG
PLoS One; 2015; 10(10):e0140528. PubMed ID: 26466313
[TBL] [Abstract][Full Text] [Related]
37. PLEKHG5 regulates autophagy, survival and MGMT expression in U251-MG glioblastoma cells.
Witte KE; Slotta C; Lütkemeyer M; Kitke A; Coras R; Simon M; Kaltschmidt C; Kaltschmidt B
Sci Rep; 2020 Dec; 10(1):21858. PubMed ID: 33318498
[TBL] [Abstract][Full Text] [Related]
38. Cilengitide in glioblastoma: when did it fail?
Chinot OL
Lancet Oncol; 2014 Sep; 15(10):1044-5. PubMed ID: 25163907
[No Abstract] [Full Text] [Related]
39. Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting.
Huang Z; Cheng L; Guryanova OA; Wu Q; Bao S
Protein Cell; 2010 Jul; 1(7):638-55. PubMed ID: 21203936
[TBL] [Abstract][Full Text] [Related]
40. Novel approaches for glioblastoma treatment: Focus on tumor heterogeneity, treatment resistance, and computational tools.
Valdebenito S; D'Amico D; Eugenin E
Cancer Rep (Hoboken); 2019 Dec; 2(6):e1220. PubMed ID: 32729241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
